Previous 10 | Next 10 |
2023-11-09 07:51:10 ET More on Gossamer Bio Seeking Alpha’s Quant Rating on Gossamer Bio Historical earnings data for Gossamer Bio Financial information for Gossamer Bio For further details see: Gossamer Bio GAAP EPS of -$0.21 beats by $0.05
- Phase 3 PROSERA Site Activations Proceeding Ahead of Schedule; First Dosing Expected in 4Q23 - - Additional Data from TORREY Open-Label Extension Expected in 4Q23 - - $329 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2023 - Gossa...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Gossamer Bio Inc. (GOSS) is expected to report $-0.2 for Q3 2023
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medic...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that data from its functional respiratory imaging, or FRI, sub-study of the s...
2023-08-08 17:22:12 ET Gossamer Bio press release ( NASDAQ: GOSS ): Q2 GAAP EPS of -$0.45 beats by $0.04 . $374 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2023, Pro Forma for Gross Proceeds of $212 Million from a Private Placement Fin...
- Seralutinib Phase 3 PROSERA Study in PAH Patients Expected to Initiate in 3Q23 - - Additional Data from TORREY Open-Label Extension Expected in 4Q23 or 1Q24 - - $374 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2023, Pro Forma for Gross Proceeds ...
2023-07-27 11:49:43 ET Gossamer Bio ( NASDAQ: GOSS ) fell ~4% Thursday noon after UBS downgraded the biopharmaceutical company, having said the next few years are more about execution. The ratings agency lowered the recommendation on the company to Neutral from Buy, and d...
News, Short Squeeze, Breakout and More Instantly...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present up...
- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 - - TORREY Phase 2 PAH Results Published in Lancet ...
Gossamer Bio Inc (NASDAQ:GOSS) and Italy-based Chiesi Farmaceutici S.p.A, have entered a global collaboration and license agreement ...